Inhibition of PI3Kδ improves systemic lupus in mice

Inflammation

Volumn 37, Issue 3, 2014, Pages 978-983

  Wang, Yanxia ^a   Zhang, Lei ^a   Wei, Ping ^a   Zhang, Huailiang ^b   Liu, Cuijie ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b Department of Internal Medicine   (China)

Author keywords

BXSB mice; organ damage; p110 ; phosphoinositide 3 kinase; systemic lupus erythematosus

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; AUTOANTIBODY; CELL NUCLEUS ANTIGEN; COMPLEMENT COMPONENT C3; CREATININE; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PROTEIN KINASE B; UNCLASSIFIED DRUG; ADENINE; ANTINUCLEAR ANTIBODY; CCL2 PROTEIN, MOUSE; IL1B PROTEIN, MOUSE; PIK3CD PROTEIN, MOUSE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HISTOPATHOLOGY; KIDNEY FUNCTION; LIVER INJURY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; DRUG EFFECTS; IMMUNOLOGY; KIDNEY; KIDNEY FUNCTION TEST; LIVER; LUPUS ERYTHEMATOSUS, SYSTEMIC; MORTALITY; PATHOLOGY; PHOSPHORYLATION;

MUS;

ADENINE; ANIMALS; ANTIBODIES, ANTINUCLEAR; CHEMOKINE CCL2; CREATININE; INTERLEUKIN-17; INTERLEUKIN-1BETA; KIDNEY; KIDNEY FUNCTION TESTS; LIVER; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEINURIA; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES;

EID: 84902551436     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9818-0     Document Type: Article

References (25)

1. Gaitonde, S., D. Samols, and I. Kushner. 2008. C-reactive protein and systemic lupus erythematosus. Arthritis and Rheumatism 59: 1814-1820.
2. Costenbader, K.H., A. Desai, G.S. Alarcón, L.T. Hiraki, T. Shaykevich, M.A. Brookhart, et al. 2011. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis and Rheumatism 63: 1681-1688.
3. Merrill, J.T., E.M. Ginzler, D.J. Wallace, J.D. McKay, J.R. Lisse, C. Aranow, et al. 2012. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis and Rheumatism 64: 3364-3373.
4. Yanaba, K., J.D. Bouaziz, T. Matsushita, C.M. Magro, E.W. St Clair, and T.F. Tedder. 2008. B- lymphocyte contributions to human auto-immune disease. Immunology Reviews 223: 284-299.
5. Puri, K.D., and M.R. Gold. 2012. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Frontiers in Immunology 3: 256.
6. Randis, T.M., K.D. Puri, H. Zhou, and T.G. Diacovo. 2008. Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. European Journal of Immunology 38: 1215-1224.
7. Park, S.J., K.S. Lee, S.R. Kim, K.H. Min, H. Moon, M.H. Lee, et al. 2010. Phosphoinositide 3-kinase delta inhibitor suppresses interleukin-17 expression in a murine asthma model. European Respiratory Journal 36: 1448-1459.
8. Haylock-Jacobs, S., I. Comerford, M. Bunting, E. Kara, S. Townley, M. Klingler-Hoffmann, et al. 2011. PI3Kdelta drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. Journal of Autoimmunity 36: 278-287.
9. Durand, C.A., M.J. Richer, K. Brenker, M. Graves, I. Shanina, K. Choi, et al. 2013. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice. Autoimmunity 46: 62-73.
10. Kang, B.N., S.G. Ha, X.N. Ge, M. Reza Hosseinkhani, N.S. Bahaie, Y. Greenberg, et al. 2012. The p110ä subunit of PI3K regulates bone marrow-derived eosinophil trafficking and airway eosinophilia in allergen-challenged mice. American Journal of Physiology - Lung Cellular and Molecular Physiology 302: L1179-L1191.
11. Sekine, H., K.L. Graham, S. Zhao, M.K. Elliott, P. Ruiz, P.J. Utz, et al. 2006. Role of MHC-linked genes in autoantigen selection and renal disease in amurine model of systemic lupus erythematosus. Journal of Immunology 177: 7423-7434.
12. Arefieva, T.I., N.B. Kukhtina, O.A. Antonova, and T.L. Krasnikova. 2005. MCP-1-stimulated chemotaxis of monocytic and endothelial cells is dependent on activation of different signaling cascades. Cytokine 31: 439-446.
13. Zeng, G., F.H. Nystrom, L.V. Ravichandran, L.N. Cong, M. Kirby, H. Mostowski, et al. 2000. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101: 1539-1545.
14. Markopoulou, A., and V.C. Kyttaris. 2013. Small molecules in the treatment of systemic lupus erythematosus. Clinical Immunology 148: 359-368.
15. Fung-Leung, W.P. 2011. Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function. Cellular Signalling 23: 603-608.
16. Puri, K.D., T.A. Doggett, J. Douangpanya, Y. Hou, W.T. Tino, T. Wilson, et al. 2004. Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood 103: 3448-3456.
17. Ali, K., M. Camps, W.P. Pearce, H. Ji, T. Rückle, N. Kuehn, et al. 2008. Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. Journal of Immunology 180: 2538-2544.
18. Okkenhaug, K., D.T. Patton, A. Bilancio, F. Garçon, W.C. Rowan, and B. Vanhaesebroeck. 2006. The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. Journal of Immunology 177: 5122-5128.
19. Soond, D.R., E. Bjørgo, K. Moltu, V.Q. Dale, D.T. Patton, K.M. Torgersen, et al. 2010. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115: 2203-2213.
20. Ambrosi, A., A. Espinosa, and M. Wahren-Herlenius. 2012. IL-17: a new actor in IFN-driven systemic autoimmune diseases. European Journal of Immunology 42: 2274-2284.
21. Suárez-Fueyo, A., D.F. Barber, J. Martínez-Ara, A.C. Zea-Mendoza, and A.C. Carrera. 2011. Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. Journal of Immunology 187: 2376-2385.
22. Badr, G., H. Saad, H. Waly, K. Hassan, H. Abdel-Tawab, I.M. Alhazza, et al. 2010. Type I interferon (IFN-alpha/beta) rescues B-lymphocytes from apoptosis via PI3Kdelta/Akt, Rho-A, NFkappaB and Bcl-2/Bcl(XL). Cellular Immunology 263: 31-40.
23. Thacker, S.G., W. Zhao, C.K. Smith, W. Luo, H. Wang, A. Vivekanandan-Giri, B.J. Rabquer, A.E. Koch, S. Pennathur, A. Davidson, D.T. Eitzman, and M.J. Kaplan. 2012. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis and Rheumatism 64: 2975-2985.
24. Baccala, R., R.Gonzalez-Quintial, R.D. Schreiber, B.R. Lawson, D.H. Kono, and A.N. Theofilopoulos. 2012. Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice. Journal of Immunology 189: 5976-5984.
25. Ramanujam, M., P. Kahn, W. Huang, H. Tao, M.P. Madaio, S.M. Factor, et al. 2009. Interferon-alpha treatment of female (NZW x BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation. Arthritis and Rheumatism 60: 1096-1101.